Alyeska Investment Group
TVTX icon

Alyeska Investment Group’s Travere Therapeutics TVTX Stock Holding History

Alyeska Investment Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-125,000
Closed -$3M – 577
2015
Q1 		$3M Buy
+125,000
New +$1.91M 0.04% 335

Other funds holding TVTX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AC
Amici Capital New York $257M AUM 4.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group's TVTX Position: Q2 2015 in Review

Alyeska Investment Group sold out of Travere Therapeutics (TVTX) in Q2 2015, closing a stake of 125,000 shares — an estimated $3M sold.

Alyeska Investment Group first reported a position in TVTX in Q1 2015 and held it in 1 quarter. The position peaked at $3M in Q1 2015. 126 funds tracked by Wall St. Rank hold TVTX as of Q2 2015.

  • Alyeska Investment Group reported no remaining Travere Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Alyeska Investment Group sold 125,000 Travere Therapeutics shares in Q2 2015, an estimated $3M.
  • Alyeska Investment Group first reported a position in Travere Therapeutics in Q1 2015 and held it in 1 quarter.
  • Alyeska Investment Group's Travere Therapeutics position peaked at $3M in Q1 2015.
  • 126 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2015.

Based on Alyeska Investment Group's 13F filing for Q2 2015, filed 14 Aug 2015.